本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2026/11/61 分钟阅读
Combinations of iOnctura's roginolisib revert immune suppression in immunotherapy-resistant NSCLC
本地自动翻译 · 来源原始语言
摘要
Late breaking data from ongoing Phase I/II PULMO-01, the first clinical study of conformation-selective PI3Kδ inhibitor roginolisib in immunotherapy-resistant non-small cell lung cancer (NSCLC), presented at SITC…
来源原始语言: PR Newswire UK — News Releases打开原始公告 →